Dendrofalconerol A sensitizes anoikis and inhibits migration in lung cancer cells

被引:18
作者
Pengpaeng, Premkamol [1 ,2 ]
Sritularak, Boonchoo [2 ,3 ]
Chanvorachote, Pithi [1 ,2 ,4 ]
机构
[1] Chulalongkorn Univ, Dept Physiol & Pharmacol, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok 10330, Thailand
[3] Chulalongkorn Univ, Dept Pharmacognosy & Pharmaceut Bot, Bangkok 10330, Thailand
[4] Chulalongkorn Univ, Cell Based Drug & Hlth Prod Dev Res Unit, Bangkok 10330, Thailand
关键词
Dendrobium falconeri; Metastasis; Dendrofalconerol A; Anoikis; Migration; Lung cancer; FOCAL ADHESION KINASE; RESISTANCE; EXPRESSION; METASTASIS; CARCINOMA; TARGET; MCL-1; AKT; PHOSPHATASES; MELANOMA;
D O I
10.1007/s11418-014-0876-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Resistance to anoikis, enhanced cell motility, and growth in anchorage-independent conditions are hallmarks of highly metastatic cancer cells. The present study demonstrates the anoikis-sensitizing and anti-migration activities of dendrofalconerol A (DF-A), a pure bis(bibenzyl) isolated from the stem of Dendrobium falconeri (Orchidaceae), and its underlying mechanisms in human lung cancer H460 cells. DF-A at non-toxic concentrations significantly increased the anoikis response of the cancer cells, but caused no toxic effect on normal keratinocytes. In addition, DF-A significantly inhibited the growth of lung cancer cells in anchorage-independent conditions. Western blot analysis revealed that the anoikis-sensitizing effect of such a compound involves its ability to suppress survival signals as well as anti-apoptotic proteins, namely, activated protein kinase B (Akt) and Bcl-2. Furthermore, DF-A decreased caveolin-1 (Cav-1), a protein responsible for aggressiveness, while having no effect on Bax, Mcl-1, and activated Erk (p42/44) proteins. In the case of cell motility, DF-A exhibited strong anti-migration activity with the mechanism involving suppression of pFAK and Rho-GTP, but had no effect on Rac-GTP in lung cancer cells. Taken together, DF-A possesses anoikis-sensitizing activity along with anti-migration effects, and may be developed as a novel active compound for cancer treatment.
引用
收藏
页码:178 / 190
页数:13
相关论文
共 37 条
  • [1] Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
    Boisvert-Adamo, Karen
    Longmate, Whitney
    Abel, Ethan V.
    Aplin, Andrew E.
    [J]. MOLECULAR CANCER RESEARCH, 2009, 7 (04) : 549 - 556
  • [2] Anoikis: a potential target to prevent lung cancer metastasis?
    Chanvorachote, Pithi
    Chunhacha, Preedakorn
    Pongrakhananon, Varisa
    [J]. LUNG CANCER MANAGEMENT, 2013, 2 (03) : 169 - 171
  • [3] Nitric Oxide Regulates Lung Carcinoma Cell Anoikis through Inhibition of Ubiquitin-Proteasomal Degradation of Caveolin-1
    Chanvorachote, Pithi
    Nimmannit, Ubonthip
    Lu, Yongju
    Talbott, Siera
    Jiang, Bing-Hua
    Rojanasakul, Yon
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (41) : 28476 - 28484
  • [4] Imperatorin sensitizes anoikis and inhibits anchorage-independent growth of lung cancer cells
    Choochuay, Kanuengnit
    Chunhacha, Preedakorn
    Pongrakhananon, Varisa
    Luechapudiporn, Rataya
    Chanvorachote, Pithi
    [J]. JOURNAL OF NATURAL MEDICINES, 2013, 67 (03) : 599 - 606
  • [5] Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells
    Chunhacha, Preedakorn
    Pongrakhananon, Varisa
    Rojanasakul, Yon
    Chanvorachote, Pithi
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2012, 302 (09): : C1284 - C1292
  • [6] PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation
    Diaz-Montero, C. Marcela
    Wygant, James N.
    McIntyre, Bradley W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1491 - 1500
  • [7] Anoikis mechanisms
    Frisch, SM
    Screaton, RA
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (05) : 555 - 562
  • [8] Bcl-2 expression in metastatic malignant melanoma.: Importance for the therapeutic efficacy of biochemotherapy
    Håkansson, A
    Gustafsson, B
    Abdiu, A
    Krysander, L
    Håkansson, L
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (04) : 249 - 254
  • [9] Halim H, 2012, ANTICANCER RES, V32, P1649
  • [10] Halim H, 2011, ANTICANCER RES, V31, P193